Biotie Therapies - Total number of voting rights and capital

Change in the number of votes relating to Biotie Therapies Corp.'s shares

BIOTIE THERAPIES CORP.                  Stock Exchange Release            6 May
2015 at 9.15 am

Change in the number of votes relating to Biotie Therapies Corp.'s shares

Biotie Therapies Corp. ("Biotie" or the "Company") has conveyed Biotie shares
held as treasury shares, that were issued on 17 December 2014, pursuant to the
Stock Option Plan 2011 (the "Plan") as follows:

 Shares conveyed Cumulative shares Remaining shares to
                 conveyed since 17 be conveyed
                 December 2014

 388,750         2,209,875         237,500

Under the Stock Option Plan 2011, the owners of the stock options may subscribe
for a maximum total of 7,401,000 new shares in the Company or existing shares
held by the Company, of which a total of 1,844,250 were subscribed for in 2014.
A total of 388,750 shares have been subscribed for during the period 23 April
2015 and 5 May 2015 and 388,750 of the treasury shares will be used for these
share subscriptions. The subscription price of EUR 0.01 per share has been fully
paid by the employee and the EUR 3887.50 funds received will be credited to the
Company's reserve for non-restricted equity. Due to share issues already made
pursuant to the Stock Option Plan 2011, forfeitures and some of the instruments
based on the plan having been left unallocated, a maximum of 2,195,000 shares
may still be issued pursuant to the Stock Option Plan 2011.

The conveyed shares previously held as treasury shares have not carried any
voting rights. The conveyance does not affect the number of registered shares.
After the conveyances the changes are as follows:

 Increase in number    Total amount of Number of the     Total number
 of outstanding shares voting rights   Company's shares  of registered
                                       held by the Group shares

 388,750               452,990,234     2,977,940         455,968,174


Turku, 6 May 2015

Biotie Therapies Corp.
Timo Veromaa, President and CEO

For further information, please contact:
Virve Nurmi, Investor Relations Manager, Biotie Therapies Corp.
tel. +358 2 274 8900, e-mail: virve.nurmi@biotie.com
www.biotie.com

DISTRIBUTION:
NASDAQ OMX Helsinki Ltd
Main Media


[HUG#1918702]